Immunotherapeutic strategies for EBV-associated malignancies.
Advances in our understanding of the role of cytotoxic T lymphocytes (CTLs) in the control of Epstein-Barr virus (EBV)-associated malignancies and the overall biology of these diseases have led to the development of novel therapeutic strategies designed to specifically target viral antigens expressed in these malignancies. Long-term success of many of these strategies is constrained by the latency phenotypes adopted by different diseases. Adoptive transfer of polyclonal virus-specific CTLs has been used successfully to reverse the outgrowth of malignancies such as post-transplant lymphoproliferative disease (PTLD). On the other hand, limited viral gene expression in other EBV-associated malignancies such as Burkitt's lymphoma, Hodgkin's disease and nasopharyngeal carcinoma limits the efficacy of immunotherapeutic strategies used for PTLD. Preclinical studies based on specific targeting of viral antigens expressed in these malignancies have provided very encouraging results and thus are likely to serve as an important platform for the treatment of human patients.
Khanna
R
R
Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Bancroft Centre, 300 Herston Road, Herston (Qld) 4006, Brisbane, Australia. rajivK@qimr.edu.au
Tellam
J
J
Duraiswamy
J
J
Cooper
L
L
D019264:Adoptive Transfer; D000818:Animals; D002051:Burkitt Lymphoma / Q000628:therapy; D002277:Carcinoma / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008954:Models, Biological; D009303:Nasopharyngeal Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000628:therapy* / Q000821:virology*; D010641:Phenotype; D013997:Time Factors